Use of Incretin Therapy in the Treatment of Type 2 Diabetes Mellitus

Michelle P. Zappas, Meredith Gentes, Benita Walton-Moss

Research output: Contribution to journalArticlepeer-review

Abstract

Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase 4 inhibitors are 2 of 6 second-line medication options in diabetes management according to the 2016 American Diabetes Association guidelines. Providers must take many factors into consideration when choosing a treatment regimen, including patient preference, cost and insurance coverage, efficacy, and tolerability. Side effects, such as hypoglycemia and weight gain, often contribute to lack of control and poor adherence. Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase 4 inhibitors are well-tolerated options that improve glycemic control with a low incidence of hypoglycemia and weight gain. In this article we review the similarities, differences, advantages, and disadvantages of the incretin therapies.

Original languageEnglish (US)
Pages (from-to)418-424
Number of pages7
JournalJournal for Nurse Practitioners
Volume13
Issue number6
DOIs
StatePublished - Jun 2017

Keywords

  • DPP-4 inhibitors
  • GLP-1 receptor agonists
  • incretin therapy
  • primary care
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Advanced and Specialized Nursing

Fingerprint Dive into the research topics of 'Use of Incretin Therapy in the Treatment of Type 2 Diabetes Mellitus'. Together they form a unique fingerprint.

Cite this